70458 Federal Register / Vol. 69, No. 233 / Monday, December 6, 2004 / Notices 

CDC expects to publish final Guidelines 

in 2005.

Dated: November 24, 2004. 

James D. Seligman, 

Associate Director for Program Services, 

Centers for Disease Control and Prevention 

(CDC).

[FR Doc. 04–26710 Filed 12–3–04; 8:45 am] 

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES

Food and Drug Administration

[Docket No. 2004N–0395]

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Application for 

Participation in the Medical Device 

Fellowship Program

AGENCY: Food and Drug Administration, 

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a proposed collection of 

information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995.

DATES: Fax written comments on the 

collection of information by January 5, 

2005.

ADDRESSES: OMB is still experiencing 

significant delays in the regular mail, 

including first class and express mail, 

and messenger deliveries are not being 

accepted. To ensure that comments on 

the information collection are received, 

OMB recommends that comments be 

faxed to the Office of Information and 

Regulatory Affairs, OMB, Attn: Fumie 

Yokota, Desk Officer for FDA, FAX: 

202–395–6974.

FOR FURTHER INFORMATION CONTACT:

Peggy Robbins, Office of Management 

Programs (HFA–250), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance.

Application for Participation in the 

Medical Device Fellowship Program—

(OMB Control Number 0910–0551)—

Extension

Collecting applications for the 

Medical Device Fellowship Plan will 

allow FDA’s Center for Devices and 

Radiological Health (CDRH) to easily 

and efficiently elicit and review 

information from students and health 

care professionals who are interested in 

becoming involved in CDRH activities. 

The process will reduce the time and 

cost of submitting written 

documentation to the agency and lessen 

the likelihood of applications being 

misrouted within the agency mail 

system. It will assist the agency in 

promoting and protecting the public 

health by encouraging outside persons 

to share their expertise with CDRH.

In the Federal Register of September 

20, 2004 (69 FR 56228), FDA published 

a 60–day notice requesting public 

comment on the information collection 

provisions. No comments were received.

FDA estimates the burden of this 

collection of information as follows:

TABLE 1–ESTIMATED ANNUAL REPORTING BURDEN1

FDA Form No. 

No. of

Respondents

Annual Frequency

per Response

Total Annual

Responses

Hours per

Response Total Hours 

FDA Form 3608 100 1 100 1 100

1There are no capital costs or operating and maintenance costs associated with this collection of information.

FDA based these estimates on the 

number of inquiries that have been 

received about the program and requests 

for application forms over the past year. 

We anticipate the number of interested 

individuals and universities, and 

subsequent number of applications, to 

increase as we continue to develop an 

outreach program and an alumni base.

In addition, we would expect 

applicants who are not selected for their 

preferred term of employment to 

reapply at a later date. For these reasons 

we would expect that the number of 

applications submitted in the second 

and third years would increase 

substantially. During the first year, we 

expect to receive 100 applications. We 

believe that we will receive 

approximately 100 applications the 

second year and 100 applications the 

third year. FDA believes it will take 

individuals 1 hour to complete the 

application. This is based on similar 

applications submitted to FDA.

Dated: November 26, 2004.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 04–26672 Filed 12–3–04; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES

Food and Drug Administration

Request for Nominations for a 

Nonvoting Member Representing 

Industry Interests on a Public Advisory 

Committee

AGENCY: Food and Drug Administration, 

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug 

Administration (FDA) requests 

nominations for a nonvoting industry 

representative to serve on the Cellular 

Tissue and Gene Therapies Advisory 

Committee (formerly the Biological 

Response Modifiers Advisory 

Committee) under the purview of the 

Center for Biologics Evaluation and 

Research (CBER).

DATES: Industry organizations interested 

in participating in the selection of a 

nonvoting member to represent industry 

for the vacancy listed in this notice 

must send a letter to FDA by January 5, 

2005.

Concurrently, nomination materials 

for prospective candidates should be 

sent to FDA by January 5, 2005. A 

nominee may either be self-nominated 

or nominated by an organization to 

serve as a nonvoting industry 

representative.

ADDRESSES: All letters of interest and 

nominations should be sent to the 

contact person listed in the FOR FURTHER

INFORMATION CONTACT section of this 

document.

FOR FURTHER INFORMATION CONTACT: Gail 

Dapolito, Division of Scientific Advisors 

and Consultants (HFM–71), Food and 

Drug Administration, 1401 Rockville 

Pike, Rockville, MD 20857–1448, 301–

827–0314, e-mail: 

dapolito@cber.fda.gov.